Abstract
Sepsis is a life‐threatening condition caused by infection‐induced immune dysregulation. Clinically distinguishing sepsis from infection remains to be a challenge due to overlapping clinical features. Although miR‐186 regulates cell proliferation and apoptosis, and was predicted to target immune‐related genes, its role in sepsis is unclear. We retrospectively enrolled 21 infected patients and 20 sepsis patients. The miR‐186 level in blood cells was detected using real‐time PCR. Cytokine concentrations and lymphocyte subpopulation proportions were determined using flow cytometry. Clinical data were retrieved from medical records. The diagnostic ability of miR‐186 was compared with procalcitonin and lactate using the receiver operating characteristic (ROC) curve. miR‐186 was inhibited in human umbilical vein endothelial cells (HUVECs) and mice, followed by measurement of cytokine expression using real‐time PCR and flow cytometry. The expression level of miR‐186 was significantly higher in septic patients than in infected patients. miR‐186 showed relatively better diagnostic performance for sepsis than procalcitonin and lactate. The in vitro assay showed that LPS enhanced miR‐186 expression under a dose‐dependent manner. In vitro miR‐186 inhibition in HUVECs inhibited IL‐1β, IL‐6, and IL‐8 expression. In vivo miR‐186 inhibition significantly lowered IL‐1β concentration and natural killer cell ratio. In this study, we found that miR‐186 is significantly upregulated in sepsis and plays a regulatory role in cytokine expression, highlighting its potential as a diagnostic biomarker for sepsis.

This publication has 26 references indexed in Scilit: